BGB-3245 is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Solid Tumor. According to Globaldata, it is involved in 3 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of BGB-3245’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for BGB-3245 is expected to reach an annual total of $22 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
BGB-3245 Overview
BGB-3245 is under development for the treatment of solid tumors including colorectal cancer, advanced or metastatic colorectal cancer (CRC), advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), pancreatic participants, non-small cell lung cancer and bile duct cancer (cholangiocarcinoma) and endometrial cancer. This is a next generation RAF dimer inhibitors. The drug candidate targets a proto-oncogene B-Raf.
It was under development for melanoma.
SpringWorks Therapeutics Overview
SpringWorks Therapeutics is a drug development company that develops therapeutic medicines for various diseases. The company’s pipeline products include nirogacestat, mirdametinib, senicapoc and SW-682. Its nirogacestat is a gamma-secretase inhibitor used for the treatment of desmoid tumors; and SW-682 for hippo mutant tumors. It partners with biopharmaceutical companies, scientists, patient groups and philanthropists. SpringWorks Therapeutics is headquartered in Stamford, Connecticut, the US.
The company reported revenues of (US Dollars) US$5.5 million for the fiscal year ended December 2023 (FY2023). The operating loss of the company was US$343 million in FY2023, compared to an operating loss of US$280.7 million in FY2022. The net loss of the company was US$325.1 million in FY2023, compared to a net loss of US$277.4 million in FY2022.
The company reported revenues of US$21 million for the first quarter ended March 2024, compared to a revenue of US$5.5 million the previous quarter.
For a complete picture of BGB-3245’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
